ArticleScientific reports2026
Familial hypomagnesemia with hypercalciuria and nephrocalcinosis caused by CLDN16/CLDN19 mutations in four Chinese families.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis (FHHNC) is a rare autosomal recessive tubulopathy caused by mutations in the CLDN16 or CLDN19 genes, patients usually develop hypomagnesemia, hypercalciuria, nephrocalcinosis and renal failure early in life, and those with CLDN19 gene mutations have ocular findings in addition. Five children from four non-consanguineous Chinese Han families presenting with nephrocalcinosis and renal insufficiency were enrolled in our study. Metabolic profiling and radiology examinations were performed, in addition to whole exome sequencing (WES) used for detection of the causative variant. Clinical manifestations included polydipsia, polyuria, sterile leukocyturia or urinary tract infections. Meanwhile, hypomagnesemia was observed in the entire cohort on laboratory analyses. One patient presented with hemorrhagic ovarian cyst and proteinuria, and the renal biopsy revealed tubulointerstitial injury accompanied by glomerular sclerosis. Whole-exome sequencing identified four patients with compound heterozygosity in the CLDN16 gene, [c.217+5G>A]; [ c.218_382del], [c.130C>T]; [c.158delA] and [c.436C>T]; [c.158delA], and one patient with compound heterozygosity in the CLDN19 gene for the c.223G > S (p.G75S) variant and a novel frameshift pathogenic variant c.2;20delG (p.D74Tfs*10), which has not been previously reported in PubMed or ClinVar. Importantly, an unusual phenotype of hemorrhagic ovarian cyst was observed in one patient carrying CLDN16 mutations (c.217+5 (IVS2)G>A and c.218_382del). For the first time, we identified a novel CLDN19 pathogenic variant and documented hemorrhagic ovarian cyst in a patient with CLDN16 mutations. This study represents the largest multi-family analysis of FHHNC in a Chinese population cohort. Integrated clinical and genetic analyses of our patients might help to offer preliminary insights that contribute to refining the phenotypic and genotypic spectrum of this rare renal disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.